Royal Bank of Canada
(TSX:
RY
)
153.20
+1.16 (+0.76%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 16, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Royal Bank of Canada
< Previous
1
2
3
4
5
6
7
8
9
...
11
12
Next >
RBC Illuminates Solar Sector, Launches Coverage For 4 Solar Equipment Leaders
February 14, 2024
RBC Capital Markets highlighted favorable public policy and declining costs within the solar industry and initiated coverage on several solar equipment suppliers, including First Solar, Enphase Energy,...
Via
Benzinga
Topics
Supply Chain
Exposures
Supply Chain
RBC Capital Maintains Outperform Rating for Datadog: Here's What You Need To Know
February 14, 2024
Via
Benzinga
Earnings Preview: What To Expect To When Eye Health Company Bausch + Lomb Reports Q4 Performance Later This Month
February 09, 2024
"Bausch + Lomb's Q4 & FY 2023 results on Feb 21, 2024. Expecting $1.107 billion in sales, $0.17 EPS. RBC Capital predicts $1.159 billion revenue. Insights on Miebo launch and enhanced EBITDA margins...
Via
Benzinga
RBC Capital's Rating Upgrade Propels IGM Biosciences Into Immunology Limelight
February 09, 2024
IGM Biosciences' strategic shift to immunology with promising bispecific drug, imvotamab. RBC Capital upgraded stock to Outperform, anticipating $21 price target. Data expected in 2H 2024 validates its...
Via
Benzinga
RBC Capital Maintains Sector Perform Rating for Thomson Reuters: Here's What You Need To Know
February 09, 2024
Via
Benzinga
Preview: RBC Bearings's Earnings
February 07, 2024
Via
Benzinga
The Weird And Depressing Debate Over AS/AD
January 23, 2024
I didn’t know that hardcore RBC types had a view on this question, but today I’m more interested in Tyler’s comment on aggregate demand.
Via
Talk Markets
The Analyst Landscape: 5 Takes On RBC Bearings
January 10, 2024
Via
Benzinga
RBC Capital Maintains Outperform Rating for Ensign Group: Here's What You Need To Know
February 06, 2024
Via
Benzinga
Uber, Lyft Can Hitch A Ride Higher If Q4 Earnings Beat Wall Street Estimates
February 05, 2024
Uber reports on Wednesday, while Lyft Q4s are on Feb. 13. RBC has a sector perform rating on Lyft and an outperform rating on Uber.
Via
Benzinga
Topics
Earnings
Exposures
Financial
Capstone Copper Announces Multimillion-Dollar Financing To Support Its Chilean Expansion
February 05, 2024
Capstone Copper Corp. and Orion Mine Finance arranged a CA$375 million bought deal with RBC Capital Markets, expected to close on Feb. 8, 2024.
Via
Benzinga
RBC Capital Maintains Outperform Rating for Reinsurance Gr: Here's What You Need To Know
February 05, 2024
Via
Benzinga
RBC Capital Maintains Sector Perform Rating for Bio-Techne: Here's What You Need To Know
February 02, 2024
Via
Benzinga
RBC Capital Maintains Outperform Rating for Thermo Fisher Scientific: Here's What You Need To Know
February 01, 2024
Via
Benzinga
What's In Store For Clorox This Earnings Season? Analyst Sees Issues With Trash Bags, Cat Litter & More
January 30, 2024
Clorox faces challenges in key product categories like trash bags and cat litter, hindering recovery from the 2023 cyber-attack, according to RBC analyst Nik Modi.
Via
Benzinga
'We Stay The Course On Meta And Amazon': Analysts Preview Tech Earnings
January 29, 2024
RBC is looking for acceleration in Amazon's AWS cloud offering and expects increasing adoption of Advantage+ to be a key driver of Meta.
Via
Benzinga
Foresight to Participate in A.G.P’s Virtual Technology Conference
January 29, 2024
--News Direct--
Via
News Direct
Topics
Regulatory Compliance
Exposures
Legal
Regulatory
Foresight to Participate in A.G.P’s Virtual Technology Conference
January 29, 2024
Foresight Autonomous Holdings Ltd. (Nasdaq and TASE: FRSX) (“FRSX” or the “Company”), an innovator in automotive vision systems, today announced that management will participate in the Alliance Global...
Via
TheNewswire.com
Topics
Regulatory Compliance
Exposures
Legal
Regulatory
RBC Capital Maintains Outperform Rating for Popular: Here's What You Need To Know
January 26, 2024
Via
Benzinga
Axsome Depression Drug's Commercial Success, Pipeline Potential Undervalued, Analyst Says
January 25, 2024
Axsome Therapeutics' growth potential with RBC Capital's optimistic coverage. Auvelity's rapid Rx growth projects sales of $296M in 2024, outperforming estimates.
Via
Benzinga
RBC Capital Maintains Outperform Rating for ServiceNow: Here's What You Need To Know
January 25, 2024
Via
Benzinga
Post Event Report - The Future of Insurance Canada 2023
January 25, 2024
London, United Kingdom--(Newsfile Corp. - January 25, 2024) - In 2023 business was anything but as usual. Spiraling costs, accelerated...
Via
Newsfile
RBC Capital Maintains Sector Perform Rating for Procter & Gamble: Here's What You Need To Know
January 24, 2024
Via
Benzinga
Rio Tinto and BHP stock: Can mining giants unearth profit growth?
January 18, 2024
Analysts and mining company CEOs are upbeat about the global market for copper, iron ore and other metals, despite mining stocks' recent price declines.
Via
MarketBeat
Liver Disease Player 89Bio Downgraded: Analyst Sees Short-Term Uncertainties In Fatty Liver Drug Development
January 12, 2024
89Bio's journey in the clinical-stage biopharmaceutical space. RBC Capital Markets downgrades with insights on FGF21 drugs, pegozafermin, and 2024 uncertainties.
Via
Benzinga
RBC Capital Upgrades Taylor Morrison Home: Here's What You Need To Know
January 12, 2024
Via
Benzinga
RBC Capital Maintains Outperform Rating for Realty Income: Here's What You Need To Know
January 11, 2024
Via
Benzinga
BlackBerry Analyst Cites Concerns On Visibility, Financing Despite Q3 Earnings Beat: Here Are The Details
December 21, 2023
RBC Capital Markets analyst Paul Treiber maintained the Sector Perform rating on BlackBerry Ltd (NYSE: BB) and cut the price target to $4 from $4.50 despite the third-quarter
Via
Benzinga
Fusion's Pharma's Targeted Cancer Therapy Potential Gets This Analyst Bullish, Sees 100% Upside
December 20, 2023
RBC Capital Markets initiated coverage on Fusion Pharmaceuticals Inc (NASDAQ: FUSN), saying the radiopharmaceutical industry is a burgeoning area in therapeutics following the green light for Novartis...
Via
Benzinga
RBC Capital Maintains Outperform Rating for FirstService: Here's What You Need To Know
December 20, 2023
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
9
...
11
12
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.